Jay Stoudemire

2.2k total citations · 1 hit paper
14 papers, 1.1k citations indexed

About

Jay Stoudemire is a scholar working on Molecular Biology, Cancer Research and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Jay Stoudemire has authored 14 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Cancer Research and 3 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Jay Stoudemire's work include MicroRNA in disease regulation (8 papers), RNA modifications and cancer (5 papers) and RNA Interference and Gene Delivery (4 papers). Jay Stoudemire is often cited by papers focused on MicroRNA in disease regulation (8 papers), RNA modifications and cancer (5 papers) and RNA Interference and Gene Delivery (4 papers). Jay Stoudemire collaborates with scholars based in United States, South Korea and Japan. Jay Stoudemire's co-authors include Andreas G. Bader, Mitesh J. Borad, Jasgit C. Sachdev, Sinil Kim, David S. Hong, Andrew Brenner, Stephen M. Smith, Yoon‐Koo Kang, Muhammad S. Beg and David T. Brown and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Analytical Chemistry.

In The Last Decade

Jay Stoudemire

14 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

2016 682 citations Muhammad S. Beg, Andrew Brenner et al. Investigational New Drugs profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jay Stoudemire United States	7	901	791	81	79	43	14	1.1k
Michael Omotola United States	3	1.3k 1.4×	1.2k 1.5×	74 0.9×	56 0.7×	27 0.6×	4	1.5k
Tong-Tao Yang China	12	881 1.0×	756 1.0×	151 1.9×	100 1.3×	32 0.7×	22	1.2k
Kristina Kapinas United States	8	692 0.8×	529 0.7×	94 1.2×	43 0.5×	23 0.5×	9	894
Jonathan J. Sze Hong Kong	13	540 0.6×	428 0.5×	170 2.1×	85 1.1×	22 0.5×	16	775
Shunwu Fan China	11	583 0.6×	453 0.6×	52 0.6×	40 0.5×	42 1.0×	14	780
Alessandra Affinito Italy	16	715 0.8×	536 0.7×	130 1.6×	65 0.8×	16 0.4×	24	890
Fatma Valiyeva Puerto Rico	13	490 0.5×	266 0.3×	92 1.1×	115 1.5×	54 1.3×	16	682
Shyam Bandari United States	11	725 0.8×	335 0.4×	75 0.9×	92 1.2×	13 0.3×	17	851
Yi Ba China	11	503 0.6×	322 0.4×	98 1.2×	119 1.5×	16 0.4×	23	665
Michael Alexanian United States	12	963 1.1×	630 0.8×	82 1.0×	36 0.5×	16 0.4×	18	1.2k

Countries citing papers authored by Jay Stoudemire

Since Specialization

Citations

This map shows the geographic impact of Jay Stoudemire's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Stoudemire with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Stoudemire more than expected).

Fields of papers citing papers by Jay Stoudemire

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Stoudemire. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Stoudemire. The network helps show where Jay Stoudemire may publish in the future.

Co-authorship network of co-authors of Jay Stoudemire

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Stoudemire. A scholar is included among the top collaborators of Jay Stoudemire based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Stoudemire. Jay Stoudemire is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Daver, Naval, Hongliang Cai, Ken Eguchi, et al.. (2022). Phase 1/2, open-label, dose-escalation, dose-expansion study of menin inhibitor DSP-5336 in adult patients with acute leukemia with and without mixed-lineage leukemia (MLL)-rearrangement (r) or nucleophosmin 1 (NPM1) mutation (m).. Journal of Clinical Oncology. 40(16_suppl). TPS7066–TPS7066. 3 indexed citations

Daver, Naval, John Affinito, Ken Eguchi, et al.. (2022). AML-391 Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients With Acute Leukemia With and Without Mixed-Lineage Leukemia (MLL)– Rearrangement or Nucleophosmin 1 (NPM1) Mutation. Clinical Lymphoma Myeloma & Leukemia. 22. S244–S244. 1 indexed citations

Daver, Naval, Takayuki Ikezoe, Justin M. Watts, et al.. (2022). Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m). Blood. 140(Supplement 1). 3371–3372. 4 indexed citations

Daver, Naval, Hongliang Cai, Edward Dow, et al.. (2021). Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation. Blood. 138(Supplement 1). 4431–4431. 2 indexed citations

Beg, Muhammad S., Andrew Brenner, Jasgit C. Sachdev, et al.. (2016). Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investigational New Drugs. 35(2). 180–188. 682 indexed citations breakdown →

Beg, Muhammad Shaalan, David S. Hong, Jasgit C. Sachdev, et al.. (2016). First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). TPS2597–TPS2597. 9 indexed citations

Hong, David S., Yoon‐Koo Kang, Andrew Brenner, et al.. (2016). MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.. Journal of Clinical Oncology. 34(15_suppl). 2508–2508. 28 indexed citations

Beg, Muhammad Shaalan, Andrew Brenner, Jasgit C. Sachdev, et al.. (2015). Abstract C43: Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors. Molecular Cancer Therapeutics. 14(12_Supplement_2). C43–C43. 18 indexed citations

Kelnar, Kevin, et al.. (2014). Quantification of Therapeutic miRNA Mimics in Whole Blood from Nonhuman Primates. Analytical Chemistry. 86(3). 1534–1542. 57 indexed citations

10.

Beg, Muhammad Shaalan, Mitesh J. Borad, Jasgit C. Sachdev, et al.. (2014). Abstract CT327: Multicenter phase I study of MRX34, a first-in-class microRNA miR-34 mimic liposomal injection. Cancer Research. 74(19_Supplement). CT327–CT327. 19 indexed citations

11.

Brenner, A. J., Jasgit C. Sachdev, Mitesh J. Borad, et al.. (2014). 4LBA A phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis. European Journal of Cancer. 50. 196–196. 5 indexed citations

12.

Bader, Andreas G., Christopher Daige, Kevin Kelnar, et al.. (2012). Abstract 5636: Preclinical data of a microRNA-based therapy for hepatocellular carcinoma. Cancer Research. 72(8_Supplement). 5636–5636. 1 indexed citations

13.

Bader, Andreas G., et al.. (2011). Developing therapeutic microRNAs for cancer. Gene Therapy. 18(12). 1121–1126. 257 indexed citations

14.

Zhang, Yan, Xiongwen Zhang, Xiaolan Ling, et al.. (2007). A novel pan inhibitor of Bcl-2 and Mcl-1 apogossypolone (ApoG2) with superior stability and improved activity against human leukemia and lymphoma cells.. 67. 5182–5182. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact